BioTime, USCN deal

USCN granted BioTime an option to license rights to antibody-producing cell lines and related technology. BioTime said the technology could be used for large-scale manufacture of the antibody components of its PanC-Dx cancer diagnostic. BioTime and its OncoCyte Corp. subsidiary plan to launch the blood screening test for cancer markers in the EU next year. Details were not disclosed. ...